Taxane-induced peripheral neurotoxicity

Roser Velasco, Jordi Bruna

Research output: Contribution to journalReview articleResearchpeer-review

66 Citations (Scopus)


© 2014 by the authors. Taxane-derived agents are chemotherapy drugs widely employed in cancer treatment. Among them, paclitaxel and docetaxel are most commonly administered, but newer formulations are being investigated. Taxane antineoplastic activity is mainly based on the ability of the drugs to promote microtubule assembly, leading to mitotic arrest and apoptosis in cancer cells. Peripheral neurotoxicity is the major non-hematological adverse effect of taxane, often manifested as painful neuropathy experienced during treatment, and it is sometimes irreversible. Unfortunately, taxane-induced neurotoxicity is an uncertainty prior to the initiation of treatment. The present review aims to dissect current knowledge on real incidence, underlying pathophysiology, clinical features and predisposing factors related with the development of taxane-induced neuropathy.
Original languageEnglish
Pages (from-to)152-169
Issue number2
Publication statusPublished - 28 Apr 2015


  • Cabazitaxel
  • Chemotherapy-induced peripheral neuropathy
  • Docetaxel
  • Nab-paclitaxel
  • Neurotoxicity
  • Paclitaxel
  • Peripheral neuropathy
  • Taxane
  • Taxane-induced peripheral neuropathy


Dive into the research topics of 'Taxane-induced peripheral neurotoxicity'. Together they form a unique fingerprint.

Cite this